New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
06:28 EDTTEVAGeneric Copaxone approval likely later than expected, says Citigroup
Citigroup says the FDA has recently requested incremental data from the Copaxone generic filers, including both gene expression and immunogenicity data. Citi expects the first generic approval towards the end of 2014 at the earliest, later than the current Street expectations of Q3. Citi reiterates a Buy rating on Teva shares with a $70 price target.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use